z-logo
open-access-imgOpen Access
β-Blockers, Pneumonia, and Outcome After Ischemic Stroke
Author(s) -
M. Sýkora,
Pavel Šiarnik,
Jennifer Diedler,
Kennedy R. Lees,
Andrei V. Alexandrov,
Philip M. Bath,
E. Bluhmki,
Natan M. Bornstein,
L. Claesson,
Stephen M. Davis,
Geoffrey A. Donnan,
H. C. Diener,
M. Fisher,
M. D. Ginsberg,
Barbara Gregson,
J. Grotta,
Werner Hacke,
M.G. Hennerici,
Marc Hommel,
Markku Kaste,
Patrick Lyden,
John R. Marler,
Keith W. Muir,
Roberto Sacco,
Ashfaq Shuaib,
Philip Teal,
N.G. Wahlgren,
Steven Warach,
C. Weimar
Publication year - 2015
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.114.008260
Subject(s) - medicine , stroke (engine) , pneumonia , ischemic stroke , cardiology , intensive care medicine , ischemia , mechanical engineering , engineering
Increased sympathetic drive after stroke is involved in the pathophysiology of several complications including poststroke immunudepression. β-Blocker (BB) therapy has been suggested to have neuroprotective properties and to decrease infectious complications after stroke. We aimed to examine the effects of random pre- and on-stroke BB exposure on mortality, functional outcome, and occurrence of pneumonia after ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom